Jonathan A. Ledermann, BSc, MD, FRCP, discusses the additive effects of olaparib (Lynparza) and bevacizumab (Avastin) in advanced ovarian cancer.
Jonathan A. Ledermann, BSc, MD, FRCP
Advertisement
Articles by Jonathan A. Ledermann, BSc, MD, FRCP
Jonathan A. Ledermann, BSc, MD, FRCP, professor of medical oncology, UCL Cancer Institute, University College London, and an honorary consultant medical oncologist, UCL Hospitals, discusses responses to rucaparib (Rubraca) maintenance in ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Ledermann on Response to Rucaparib in Recurrent Ovarian CancerPublished: March 7th 2020 | Updated:
Dr. Ledermann on the Additive Effects of Olaparib and Bevacizumab in Ovarian CancerPublished: March 14th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5